Pasar al contenido principal

EL RECEPTOR DE MELANOCORTINAS 1 Y MAHOGUNINA COMO DETERMINANTES DEL FENOTIPO DE LOS MELANOCITOS Y LAS CELULAS DE MELANOMA.

SAF2015-67092-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario UNIVERSIDAD DE MURCIA
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Functional interplay between secreted ligands and receptors in melanoma

  • Herraiz, Cecilia
  • Jiménez-Cervantes, Celia
  • Sánchez-Laorden, Berta
  • García-Borrón, José C.
Melanoma, the most aggressive form of skin cancer, results from the malignant transformation of melanocytes located in the basement membrane separating the epidermal and dermal skin compartments. Cutaneous melanoma is often initiated by solar ultraviolet radiation (UVR)-induced mutations. Melanocytes intimately interact with keratinocytes, which provide growth factors and melanocortin peptides acting as paracrine regulators of proliferation and differentiation. Keratinocyte-derived melanocortins activate melanocortin-1 receptor (MC1R) to protect melanocytes from the carcinogenic effect of UVR. Accordingly, MC1R is a major determinant of susceptibility to melanoma. Despite extensive phenotypic heterogeneity and high mutation loads, the molecular basis of melanomagenesis and the molecules mediating the crosstalk between melanoma and stromal cells are relatively well understood. Mutations of intracellular effectors of receptor tyrosine kinase (RTK) signalling, notably NRAS and BRAF, are major driver events more frequent than mutations in RTKs. Nevertheless, melanomas often display aberrant signalling from RTKs such as KIT, ERRB1-4, FGFR, MET and PDGFR, which contribute to disease progression and resistance to targeted therapies. Progress has also been made to unravel the role of the tumour secretome in preparing the metastatic niche. However, key aspects of the melanoma-stroma interplay, such as the molecular determinants of dormancy, remain poorly understood., Work by the authors is supported by grants SAF2015-67092-R (to CJ-C and JCG-B) and SAF2016-75702-R (to BS-L) from the Mineco (Spain) and FEDER (European Community) and 19875/GERM/15 from the Fundación Seneca, Comunidad Autónoma Región de Murcia (CARM) (to CJ-C and JCG-B). C Herraiz holds a Juan de la Cierva-Incorporación fellowship from Mineco (Spain)., Peer reviewed